Bevacizumab Biosimilar Mixture from China
A bulk mixed immunological product with bevacizumab monoclonal antibodies targeting VEGF for colorectal cancer therapy. It is not put up in measured doses or retail packings, and is classified as a mixed immunological product per chapter note 2.
Duty Rate — China → Canada
0%
Import Tips
• Confirm the product is a mixture containing bevacizumab MABs, as defined in chapter note 2
• Ensure it is not in retail packings
• Maintain detailed batch records for CBSA inspection